On December 21, 2020 Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) and Alloy Therapeutics ("Alloy"), a biotechnology company dedicated to empowering scientists in the relentless pursuit of making better medicines for all, reported that the companies have entered into a technology partnership to expand Evotec’s antibody discovery platform (Press release, Evotec, DEC 21, 2020, View Source;announcements/press-releases/p/evotec-partners-with-alloy-therapeutics-to-expand-its-antibody-discovery-platform-6010 [SID1234573189]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Under the terms of the agreement, Evotec receives access to Alloy’s ATX-Gx mouse platform to enable best-in-class in vivo discovery of fully human monoclonal antibodies for use in both its proprietary as well as partnered R&D projects across more than 15 disease areas. ATX-Gx comprises a suite of highly immunocompetent transgenic mice strains that together offer (i) fully human heavy chain repertoire, (ii) human kappa and human lambda chain repertoire, (iii) haplotype diversity, and (iv) limited immunodominance. The integration of ATX-Gx with Evotec’s existing platform capabilities in the area of antibody discovery, especially J.HALSM, Just – Evotec Biologics’ humanoid antibody library for in vitro antibody discovery, is expected to deliver numerous starting points for innovative discovery projects across indications.
With the acquisition of Just – Evotec Biologics in 2019, Evotec made a major push into biologics, and has successfully built a fully-integrated platform to drive monoclonal antibody ("mAb") programmes from concept through commercialisation. ATX-Gx adds to Evotec’s comprehensive suite of large molecule discovery tools, disease biology, state-of-the-art cell line development, machine learning design tools, manufacturing, pre-clinical IND-enabling studies, as well as FIH clinical support, and commercialisation.
Dr Craig Johnstone, Chief Operating Officer of Evotec, commented: "Successful, fully-integrated drug discovery and development requires specific expertise as well as cutting-edge technologies and capabilities. We are delighted to be able to offer the ATX-Gx platform as an important addition to our existing world-class biologics discovery offerings."
Errik Anderson, Chief Executive Officer, Founder and Chairman of Alloy Therapeutics said: "Alloy’s mission is to make medicines through collaboration by democratizing access to foundational drug discovery platforms and services. Integrating ATX-Gx with Evotec’s broad biologics discovery capabilities will expedite the translation of therapeutic antibody programs from concept to commercialization for Evotec scientist customers."